Impact of SGLT2 on Glucosuria in HNF1A-MODY

Key facts

Sponsor

Steno Diabetes Center Copenhagen

Principal Investigator

Tina Vilsbøll

Steno Diabetes Center Copenhagen

Intervention

Hyperglycaemic clamp(other)

Enrollment

21 target

Eligibility

18 years · All sexes

Timeline

2022 – 2023

Study locations (1)

• Steno Diabetes Center Copenhagen, Herlev, Denmark

Collaborators

University of Copenhagen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for MODY

Additional recruiting or active studies for the same condition.

• RECRUITINGEARLY PHASE1NCT06609356
  Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
  Vanderbilt University Medical Center
• RECRUITINGNANCT06118931
  Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control
  University of Toronto
• RECRUITINGPHASE2NCT07029009
  Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
  Mansa
• ACTIVE NOT RECRUITINGPHASE3NCT06767735
  A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
  Gan & Lee Pharmaceuticals.
• RECRUITINGNANCT06267391
  Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
  Endogenex, Inc.
• RECRUITINGNANCT06337357
  Results of Progressive Resistance Training in Older Type 2 Diabetic Patients With Sarcopenia
  National Geriatric Hospital
• RECRUITINGNCT06111833
  Optimized Diagnosis and Precision Medicine of MODY
  Taichung Veterans General Hospital
• RECRUITINGNCT07492004
  China Monogenic Diabetes Registry
  Tianjin Medical University General Hospital

See all trials for MODY →